Ballinger at the helm at Lyndra
Plus: Bryan Stuart to lead Atavistik and updates from EnteroBiotix, PTC, CureVac, CytomX, ProKidney and more
Lyndra Therapeutics Inc. revamped its C-suite, naming President and COO Jessica Ballinger as president and CEO. Ballinger succeeds Patricia Hurter who will remain on the board and become chair of its science and technology committee. Additionally, the company promoted Richard Scranton from CMO to CMO and president of global product development, and Lindsay Beaupre to chief people and workplace operations officer from SVP of people and operations. Lyndra, which is developing risperidone to treat schizophrenia and bipolar 1 disorder, expects initial data from its pivotal trial to read out in 2H23.
Bryan Stuart became CEO and a director at Atavistik Bio Inc., which is developing allosteric modulators of metabolic proteins. Stuart succeeds Jeff Goater, a venture partner at The Column Group, who will remain on the board. Stuart was CEO at Fulcrum Therapeutics Inc. (NASDAQ:FULC), Yarra Therapeutics LLC and Kastle Therapeutics LLC...